Method and composition for treating osteoarthritis

Abstract

A method and composition for treating osteoarthritis including administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate. Ethyl (α-guanido-methyl) ethanoate provides a safe, non-toxic anti-inflammatory treatment for osteoarthritis.

What is claimed is: 
     
         1 . A method for treating an inflammatory disease comprising:
 administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate.   
     
     
         2 . The method of  claim 1 , wherein the anti-inflammatory agent is administered to the patient in an oral dosage or as a topical application. 
     
     
         3 . The method of  claim 2 , wherein the topical application is administered in an amount of about 0.5 mL to about 5 mL. 
     
     
         4 . The method of  claim 1 , wherein the patient is a human, a canine, or an animal. 
     
     
         5 . The method of  claim 1 , wherein the inflammatory disease is osteoarthritis. 
     
     
         6 . The method of  claim 2 , wherein the oral dosage is administered in an amount of about 400 mg to about 2400 mg. 
     
     
         7 . A method for reducing acute blood levels of pro-inflammatory marker, serum amyloid A, comprising:
 administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate.   
     
     
         8 . The method of  claim 7 , wherein the acute blood levels of serum amyloid A are reduced by about 30 percent to about 70 percent when compared to levels of serum amyloid A prior to administration of the anti-inflammatory agent. 
     
     
         9 . The method of  claim 7 , wherein the anti-inflammatory agent is administered to the patient in an oral dosage of about 400 mg to about 2400 mg. 
     
     
         10 . A method for reducing production and release of pro-inflammatory prostanoids in cells comprising:
 administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate.   
     
     
         11 . The method of  claim 10 , wherein the pro-inflammatory prostanoids are reduced by about 50 percent or more when compared to an amount of pro-inflammatory prostanoids prior to administration of the anti-inflammatory agent. 
     
     
         12 . The method of  claim 11 , wherein the pro-inflammatory prostanoids are reduced by about 70 percent or more when compared to an amount of pro-inflammatory prostanoids prior to administration of the anti-inflammatory agent. 
     
     
         13 . The method of  claim 10 , wherein the pro-inflammatory prostanoids comprise prostaglandin E 2 . 
     
     
         14 . A method for reducing levels of serum amyloid A, pro-inflammatory prostanoids, and tumor necrosis factor alpha in a patient, comprising:
 administering an effective amount of ethyl (α-guanido-methyl) ethanoate to the patient.   
     
     
         15 . The method of  claim 14 , wherein the levels of serum amyloid A are reduced by about 40 percent to about 60 percent when compared to levels of serum amyloid A prior to administration of the ethyl (α-guanido-methyl) ethanoate. 
     
     
         16 . The method of  claim 14 , wherein the levels of pro-inflammatory prostanoids are reduced by about 50 percent or more when compared to levels of pro-inflammatory prostanoids prior to administration of the ethyl (α-guanido-methyl) ethanoate. 
     
     
         17 . The method of  claim 14 , wherein the levels of tumor necrosis factor alpha are reduced by about 40 percent to about 60 percent when compared to levels of tumor necrosis factor alpha prior to administration of the ethyl (α-guanido-methyl) ethanoate. 
     
     
         18 . The method of  claim 14 , wherein the effective amount of ethyl (α-guanido-methyl) ethanoate is an oral dosage of about 400 mg to about 2400 mg. 
     
     
         19 . The method of  claim 14 , wherein the step of administering further comprises administering at least one other compound in conjunction with the ethyl (α-guanido-methyl) ethanoate. 
     
     
         20 . The method of  claim 19 , wherein the at least one other compound is selected from the group consisting of homeopathic compounds, co-medications, nutraceuticals, plant extracts, herbal preparations, and cosmetic agents.